GARIN6: A Potential Drug Target and Biomarker (G196472)

Target Name: GARIN6

NCBI ID: G196472

GARIN6

GARIN6: A Potential Drug Target and Biomarker

GARIN6 is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and liver. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a critical role in cellular signaling. GARIN6 has been shown to interact with several other proteins, including the neurotransmitter acetylcholine, which is involved in memory and cognitive function.

The GARIN6 gene was first identified in 2008 by researchers at the University of California, San Diego (UCSD) as a potential drug target for various psychiatric and neurological disorders, such as Alzheimer's disease, Parkinson's disease, and schizophrenia. The GARIN6 protein has been shown to interact with several neurotransmitters, including dopamine, serotonin, and GABA, which are involved in the transmission of signals in the brain.

GARIN6 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in inflammation, pain, and neurodegeneration. For example, GARIN6 has been shown to interact with the protein NF-kappa-B, which is involved in the regulation of inflammation and pain. This interaction suggests that GARIN6 may be a potential target for drugs that are designed to treat chronic pain or inflammation.

In addition to its potential drug-targeting properties, GARIN6 has also been shown to be a potential biomarker for various psychiatric and neurological disorders. For example, GARIN6 has been shown to be reduced in individuals with major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD), as well as in the brains of individuals with Alzheimer's disease. These findings suggest that GARIN6 may be a promising biomarker for the diagnosis and treatment of psychiatric and neurological disorders.

GARIN6 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in cell growth, apoptosis, and neuroplasticity. For example, GARIN6 has been shown to interact with the protein PDGF-BB, which is involved in the regulation of cell growth and differentiation. This interaction suggests that GARIN6 may be a potential target for drugs that are designed to promote neuroplasticity or inhibit cell death.

GARIN6 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in neurotransmission. For example, GARIN6 has been shown to interact with the protein neurotrophin, which is involved in the regulation of neurotransmission. This interaction suggests that GARIN6 may be a potential target for drugs that are designed to treat neurotransmission disorders.

In conclusion, GARIN6 is a protein that has been shown to interact with several neurotransmitters and play a role in the regulation of cellular signaling pathways that are involved in memory, neurodegeneration, and psychiatric disorders. These properties make GARIN6 a promising drug target and a potential biomarker for various psychiatric and neurological disorders. Further research is needed to fully understand the role of GARIN6 in the regulation of cellular signaling pathways and its potential as a drug target and biomarker.

Protein Name: Golgi Associated RAB2 Interactor Family Member 6

The "GARIN6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GARIN6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets